Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Positive

AI Analysis

Summary

Tarsus acquired Alkeus Pharmaceuticals for up to $800M, gaining a late-stage Stargardt disease therapy developed with former Vertex founder Josh Boger's involvement.

Clinical Trial Data

Phase

late-stage

Outcome Details

Tarsus acquired Alkeus for up to $800M

Importance:7/10

Sentiment:

0.60

acquisitionrare-diseaseophthalmologylate-stage-development

Related Companies

$VRTX

Read the original article

Published by BioPharma Dive on August 6, 2026 6:07 PM

Read Original